Clinical Trial Update: Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg [Phase 2]

View source ↗

Summary

Phase 2 trial comparing gefitinib 500 mg to 250 mg in NSCLC patients who had stable disease after initial 250 mg therapy. The study assesses whether a higher do…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED